Description
AOD-9604
AOD-9604 replicates the fat-burning properties of growth hormone but does not influence blood sugar levels or promote tissue growth. It enhances fat breakdown and suppresses fat storage by targeting beta-3 adrenergic receptors found on adipocytes.
Also known as: Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191
A modified segment of human growth hormone (amino acids 177–191) has been investigated for its potential impact on fat metabolism, designed to avoid the wide-ranging hormonal effects associated with full-length growth hormone.
•Status: Clinical trials have concluded, but the compound did not receive FDA approval. It was removed from FDA Category 2 in September 2024, with an anticipated reclassification to Category 1 expected by April 15, 2026, following an HHS announcement and PCAC review scheduled for July 23–24, 2026. It currently holds GRAS status. Evidence level: Supported by human clinical trials.
•Common dosage: 300 mcg per day, typically taken once daily in a fasted state, usually in the morning. Administration has been studied via both subcutaneous injection and oral routes.
•Studied applications: Fat loss, improvement in body composition, and reduction of localized fat deposits.
•Status: Clinical trials have concluded, but the compound did not receive FDA approval. It was removed from FDA Category 2 in September 2024, with an anticipated reclassification to Category 1 expected by April 15, 2026, following an HHS announcement and PCAC review scheduled for July 23–24, 2026. It currently holds GRAS status. Evidence level: Supported by human clinical trials.
•Common dosage: 300 mcg per day, typically taken once daily in a fasted state, usually in the morning. Administration has been studied via both subcutaneous injection and oral routes.
•Studied applications: Fat loss, improvement in body composition, and reduction of localized fat deposits.
Reviews
There are no reviews yet.